Centre of the pharmaverse

An all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully, while also creating a modernised healthcare landscape which yields trust and cooperation. For the most impactful communicators the future is now...
2019 – what’s in store for the life sciences industry?

Veeva’s outlook on what we can expect from the sector this year.
The promise of the PPRS

A new pricing deal for the NHS should take the squeeze off new medicines, but is still vulnerable to Brexit risks.

News

View all

Alunbrig recommended by NICE for non-small-cell lung cancer

NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.

15th February 2019

Trajenta meets primary endpoint in CAROLINA trial

Eli Lilly and Boehringer Ingelheim's Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk.

15th February 2019

Could AI predict survival of ovarian cancer patients?

Researchers have created new AI machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.

15th February 2019

NICE changes its mind on Perjeta

NICE has changed its mind and recommended Roche’s Perjeta for a new breast cancer indication.

15th February 2019

New Academy launched to fight osteoporosis

The Royal Osteoporosis Society has set up an academy to ultimately to find a cure for osteoporosis.

15th February 2019

Web Exclusives

View all

The rise of virtual pharma

The rise of virtual business models in biopharma reflects the changing face of the pharmaceutical industry - big pharma discovering and developing its own pipeline exclusively in-house no longer exists.

Medical devices regulation countdown

Cliodhna McDonough says new regulations on the horizon for medical devices in Europe present a huge challenge to manufacturers, but could also deliver improved confidence in the consistency and effectiveness of the regulatory process.

The SPC eligibility issue

The European Court should prepare for legal challenges to the ineligibility of new medical technologies for Supplementary Protection Certificates (SPCs).

Redefining Value

In today’s highly competitive healthcare market how can pharma companies stand out from the crowd? Showing brand value has never been more important.

Magazine

View more from the latest edition

Patient Files: borderline personality disorder

Joseph Capaldi was diagnosed with borderline personality disorder at the age of 23. He talks to PharmaTimes about his experiences with the condition.

SmartPeople: Dr Alexandre Lebeaut

Ipsen’s Alexandre Lebeaut discusses the highs and lows of working in pharmaceutical research and development.

A mark of success

The PharmaTimes Marketer of the Year, Communications Team of the Year, and Sales Awards 2018.

Going for gold

The birth of the PharmaTimes Medical & Scientific Excellence Awards, a new competition designed to recognise, reward and celebrate outstanding talent within medical and scientific affairs.

Centre of the pharmaverse

An all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully, while also creating a modernised healthcare landscape which yields trust and cooperation. For the most impactful communicators the future is now...

Tackling the challenge

Patient support programmes have a lot to offer pharma, but companies face big challenges in ensuring that they provide accurate, relevant and consistent data that fulfills all regulatory obligations.